Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital Read more
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Read more
Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Read more
Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-In-Class Oral MRGPR Antagonists Read more
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Read more
Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease Read more